TNC anticorps

N° du produit ABIN1109216

L’anticorps Souris Monoclonal anti-TNC a été validé pour WB, IP, IHC (p), IF et IHC (fro). Il convient pour détecter TNC dans des échantillons de Humain.

Aperçu rapide pour TNC anticorps (ABIN1109216)

Antigène: TNC (Tenascin C (TNC))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNC est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: DB7

Détail du produit anti-TNC anticorps

Specificité: The antibody recognizes the Mr 250000 and 180000 Human Tenascin polypeptides in Immunoprecipitation and in Immunoblots the Mr 250000 polypeptide. The antibody reacts with the fibrinogen-like knob-domain of Tenascin protein.

Réactivité croisée (Details): Species reactivity (tested):Human.

Purification: Ig Fraction

Immunogène: Tenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: PBS, 0.09 % Sodium Azide, 1.0 % BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C.

Détails sur TNC

Antigène: TNC (Tenascin C (TNC))

Autre désignation: Tenascin / TNC / HXB

Sujet: Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology.The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.Synonyms: Cytotactin, GMEM, GP 150-225, Glioma-associated-extracellular matrix antigen, Hexabrachion, Myotendinous antigen, Neuronectin, TN-C, Tenascin-C

ID gène: 3371

NCBI Accession: NP_002151

UniProt: P24821

Pathways: Regulation of Muscle Cell Differentiation, Regulation of Cell Size, Skeletal Muscle Fiber Development